Krystal Biotech, Inc. KRYS
305.23 USD -0.45 (-0.15%)
Regular-session close
305.23 0.00 0.00%
After hours · Nov 13, 4:26 PM ET
300.51 Day range 306.73
201.21 52-week range 378.15
- YTD
- +23.81%
- 1 year
- +51.70%
News
defenseworld.net Revolution Medicines (NASDAQ:RVMD) vs. Krystal Biotech (NASDAQ:KRYS) Head-To-Head Survey Krystal Biotech (NASDAQ: KRYS - Get Free Report) and Revolution Medicines (NASDAQ: RVMD - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two…
benzinga.com Citigroup Maintains Buy on Krystal Biotech, Lowers Price Target to $412 Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $416 to $412.
benzinga.com TD Cowen Maintains Buy on Krystal Biotech, Lowers Price Target to $380 TD Cowen analyst Ritu Baral maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $403 to $380.
benzinga.com RBC Capital Maintains Outperform on Krystal Biotech, Lowers Price Target to $375 RBC Capital analyst Lisa Walter maintains Krystal Biotech (NASDAQ:KRYS) with a Outperform and lowers the price target from $400 to $375.
benzinga.com Krystal Biotech Analyst Says Stock Weakness 'Overblown' Krystal Biotech beats Q3 earnings, but trial delays send shares lower. Analysts call the market drop overblown and highlight a potential buying opportunity.
benzinga.com Krystal Biotech Q3 2026 Earnings Call Transcript Krystal Biotech (NASDAQ:KRYS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Krystal Biotech Q3 EPS $2.05 Beats $1.77 Estimate, Sales $127.341M Beat $126.079M Estimate Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $2.05 per share which beat the analyst consensus estimate of $1.77 by 15.82 percent. This is a 22.93 percent decrease over earnings of…
benzinga.com Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott…
benzinga.com Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.65% on an annualized basis producing an average annual return of 42.52%. Currently, Krystal Biotech has a market…
benzinga.com HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $361 price target.
benzinga.com Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial Krystal Biotech reports clinical updates for KB113, showing over an 80% reduction in basal cell carcinoma lesions in Gorlin syndrome.- benzinga.com Krystal Biotech Highlights Broad Antitumor Responses With KB113 In Gorlin Syndrome Over 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113Substantial regression was observed in lesions not directly injected with KB113,…
benzinga.com $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 33.19% on an annualized basis producing an average annual return of 45.63%. Currently, Krystal Biotech has a market…
benzinga.com Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.16% on an annualized basis producing an average annual return of 44.36%. Currently, Krystal Biotech has a market…
benzinga.com Goldman Sachs Reinstates Buy on Krystal Biotech, Announces $441 Price Target Goldman Sachs analyst Andrea Newkirk reinstates Krystal Biotech (NASDAQ:KRYS) with a Buy and announces $441 price target.
benzinga.com B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $400 B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $392 to $400.- benzinga.com Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.48% on an annualized basis producing an average annual return of 43.76%. Currently, Krystal Biotech has a market…
- benzinga.com Krystal Biotech To Replace Taylor Morrison Home In The S&P MidCap 400, And Tutor Perini To Replace Krystal Biotech In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On Friday, July 24 https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20260720-1484359/1484359_tmhc-avns-46.pdf
benzinga.com Earnings Scheduled For May 4, 2026 - benzinga.com Earnings Scheduled For February 17, 2026
benzinga.com Earnings Scheduled For November 3, 2025 
benzinga.com 6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.- benzinga.com Earnings Scheduled For August 4, 2025
- benzinga.com Earnings Scheduled For May 6, 2025
- benzinga.com Earnings Scheduled For February 19, 2025
- benzinga.com ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday
- benzinga.com Earnings Scheduled For February 26, 2024 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
- benzinga.com AI, Biotech, Energy Sectors Expect M&A Revival For 2024 The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023.
- benzinga.com Earnings Scheduled For November 6, 2023 Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2023
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
- benzinga.com Stocks That Hit 52-Week Highs On Monday During Monday's morning session, 230 companies made new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Wednesday During Wednesday's morning trading, 472 companies set new 52-week highs.- benzinga.com Stocks That Hit 52-Week Highs On Friday Friday morning saw 331 companies set new 52-week highs.
benzinga.com Stocks Making New 52-Week Highs/Lows For Tuesday, Feb. 16, 2021 (Via Benzinga Pro's Signals Tool) 52-Week Highs: HomeStreet (HMST) Applied Genetic (AGTC) BTRS (BTRS) Utz Brands (UTZ) Aviat Networks (AVNW) Golden Entertainment (GDEN) Krystal Biotech (KRYS) So-Young (SY) Corning (GLW) Lightbridge- benzinga.com Stocks That Hit 52-Week Highs On Tuesday This morning 163 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Monday During the morning session on Monday, 372 stocks hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday During Thursday's morning trading, 190 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday Before 10 a.m. ET on Wednesday, 375 companies hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Friday This morning 470 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday
- benzinga.com 75 Biggest Movers From Yesterday
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday
- benzinga.com Stocks That Hit 52-Week Highs On Monday
- benzinga.com 36 Stocks Moving In Wednesday's Mid-Day Session
- benzinga.com Stocks Which Set New 52-Week High Yesterday, September 11th
- benzinga.com Stocks Which Set New 52-Week High Yesterday